We are live on
!
Find out more
BWLSA
Blue Water Life Science Advisors Portfolio holdings
AUM
$159M
1-Year Est. Return
139.66%
This Fund
S&P 500
This Quarter
Est. Return
-17.11%
1 Year Est. Return
+139.66%
3 Year Est. Return
+503.09%
5 Year Est. Return
+228.74%
10 Year Est. Return
–
AUM
$184M
AUM Growth
-$26.6M
(-13%)
Cap. Flow
+$9.99M
Cap. Flow
% of AUM
5.43%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
14
New
4
Increased
2
Reduced
2
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Adaptive Biotechnologies
ADPT
|
+$27.4M |
| 2 |
Cytek Biosciences
CTKB
|
+$20.9M |
| 3 |
Bio-Techne
TECH
|
+$17.4M |
| 4 |
Bruker
BRKR
|
+$15.8M |
| 5 |
Guardant Health
GH
|
+$8.56M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pacific Biosciences
PACB
|
+$24.2M |
| 2 |
CareDx
CDNA
|
+$20.8M |
| 3 |
10x Genomics
TXG
|
+$16.1M |
| 4 |
Natera
NTRA
|
+$7.35M |
| 5 |
Ginkgo Bioworks
DNA
|
+$7.18M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Guardant Health
GH
$21.9B
| $33.6M | 18.27% |
834,145
+172,700
| +26% | +$8.56M |
|
|
2
Natera
NTRA
$46.9B
| $32.9M | 17.89% |
929,581
-198,400
| -18% | -$7.35M |
|
|
AKYA
3
DELISTED
Akoya BioSciences
AKYA
| $27M | 14.69% |
2,104,785
+16,117
| +0.8% | +$167K |
|
|
4
Adaptive Biotechnologies
ADPT
$4.07B
| $25.2M | 13.71% |
+3,120,434
| New | +$27.4M |
|
|
5
Cytek Biosciences
CTKB
$611M
| $22.5M | 12.24% |
+2,100,000
| New | +$20.9M |
|
|
6
Bruker
BRKR
$8.94B
| $16.2M | 8.79% |
+258,000
| New | +$15.8M |
|
|
7
Bio-Techne
TECH
$11.3B
| $16.1M | 8.75% |
+186,000
| New | +$17.4M |
|
|
8
CareDx
CDNA
$2.41B
| $5.92M | 3.21% |
275,551
-748,964
| -73% | -$20.8M |
|
|
SLGC
9
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $4.48M | 2.44% |
992,086
| – | – |
|
|
10
Ginkgo Bioworks
DNA
$519M
| – | – |
-44,542
| Closed | -$7.18M |
|
|
11
Pacific Biosciences
PACB
$395M
| – | – |
-2,660,000
| Closed | -$24.2M |
|
|
12
10x Genomics
TXG
$8.1B
| – | – |
-211,917
| Closed | -$16.1M |
|
|
OLK
13
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| – | – |
-210,439
| Closed | -$3.72M |
|
|
PEAR
14
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
| – | – |
-194,686
| Closed | -$983K |
|
Similar funds
SFC
ACP
CW
SG
LA
CMMS
JWM
AC
Blue Water Life Science Advisors's Q2 2022 Portfolio in Review
As of Q2 2022, Blue Water Life Science Advisors held 14 positions worth $184M, down 13% from $211M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Blue Water Life Science Advisors deployed $9.99M of net new capital in Q2 2022, opening 4 new positions and adding to 2 existing holdings. Its largest new stake was Adaptive Biotechnologies: 3,120,434 shares worth $25.2M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was CareDx, an estimated $20.8M trimmed.
- Blue Water Life Science Advisors's largest Q2 2022 buy was Adaptive Biotechnologies: 3,120,434 shares worth $25.2M.
- Blue Water Life Science Advisors added most to Guardant Health in Q2 2022, an estimated $8.56M increase.
- Blue Water Life Science Advisors's biggest Q2 2022 reduction was CareDx, cutting an estimated $20.8M.
- Blue Water Life Science Advisors fully exited Pacific Biosciences in Q2 2022, selling an estimated $24.2M.
- Blue Water Life Science Advisors's ten largest holdings make up 100% of its $184M portfolio in Q2 2022.
- Blue Water Life Science Advisors opened 4 new positions and closed 5 in Q2 2022.
- Blue Water Life Science Advisors's portfolio value fell 13% quarter-over-quarter to $184M.
Based on Blue Water Life Science Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.